Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer

Multi-kinase inhibitors (MKIs) represent the best therapeutic option in advanced thyroid cancer patients. The therapeutic efficacy and toxicity of MKIs are very heterogeneous and are difficult to predict before starting treatment. Moreover, due to the development of severe adverse events, it is nece...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantara, Silvia, Dalmiglio, Cristina, Marzocchi, Carlotta, Sagnella, Alfonso, Brilli, Lucia, Trimarchi, Andrea, Maino, Fabio, Valerio, Laura, Castagna, Maria Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049548/
https://www.ncbi.nlm.nih.gov/pubmed/36982571
http://dx.doi.org/10.3390/ijms24065496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049548/
https://www.ncbi.nlm.nih.gov/pubmed/36982571
http://dx.doi.org/10.3390/ijms24065496

Ejemplares similares